Poor plasma stability can lead to rapid clearance, short half-lives, and poor in-vivo performance
Poor plasma stability can lead to rapid clearance, short half-lives, and poor in-vivo performance. Pharmacokinetic studies are especially challenging for these compounds as they continue to degrade even after blood is sampled from the study animal, leading to ambiguous data. In the case of prodrugs and antedrugs, rapid degradation in plasma is desirable.
If your compounds contain these plasma-labile functional groups, plasma stability should be studied:
